FDA Approves Sensus SRT-100 for Keloids

by Savitha C Muppala on  June 5, 2013 at 8:54 AM Medical Gadgets
RSS Email Print This Page Comment
Font : A-A+

The FDA has given the nod to Sensus Healthcare (Boca Raton FL) to start the marketing of its SRT-100 superficial radiotherapy system for the treatment of keloids, or scar tissue which takes shape over a wound after injury or surgical procedures. The system is employed for the treatment of non-melanoma skin cancers.
 FDA Approves Sensus SRT-100 for Keloids
FDA Approves Sensus SRT-100 for Keloids

The SRT-100 employs superficial X-rays to deliver radiation to the surface of the skin and this does not cause any pain. Anesthesia is also not required while using this system.

"Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100%. Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences," said Mark S. Nestor , MD, PhD of the Center for Cosmetic Enhancement in Aventura, FL.

SRT-100™ is the perfect treatment method for non-melanoma skin cancers and keloids, with its SharpBeam™ technology. This system ensures that only the targeted lesion is treated and the surrounding and underlying healthy tissue is not touched.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Keloids 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive